422 476
Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at
http://dx.doi.org/10.1016/ j.eururo.2017.06.012 .References
[1]
Carosella ED, Ploussard G, LeMaoult J, Desgrandchamps F. A sys- tematic review of immunotherapy in urologic cancer: evolving roles for targeting of CTLA-4, PD-1/PD-L1, and HLA-G. Eur Urol 2015;68:267–79.[2]
Malmstrom PU, Sylvester RJ, Crawford DE, et al. An individual patient data meta-analysis of the long-term outcome of random- ised studies comparing intravesical mitomycin C versus bacillus Calmette–Guerin for non-muscle-invasive bladder cancer. Eur Urol 2009;56:247–56.[3]
Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295:2516–24.[4]
Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363: 411–22.[5]
Logothetis CJ, Dexeus FH, Finn L, et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990;8:1050–5.[6]
Von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005;23:4602–8.[7]
Galsky MD, Hahn NM, Rosenberg J, et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol 2011;12:211–4.[8]
Raggi D, Miceli R, Sonpavde G, et al. Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis. Ann Oncol 2016; 27:49–61.[9]
Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016;27:v58–68.[10]
Ko JJ, XieW, Kroeger N, et al. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet Oncol 2015;16:293–300.
[11]
Horwich A, Hugosson J, De Reijke T, et al. Prostate cancer: ESMO Consensus Conference Guidelines 2012. Ann Oncol 2013;24: 1141–62.
[12]
Berthold DR, Pond GR, Soban F, DeWit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008;26:242–5.
[13]
De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazi- taxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open- label trial. Lancet 2010;376:1147–54.[14]
Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus predni- sone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2015;16:152–60.
[15]
Scher HI, Fizazi K, Saad F, et al. Increased survival with enzaluta- mide in prostate cancer after chemotherapy. N Engl J Med 2012; 367:1187–97.
[16]
Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369: 213–23.[17]
Pardoll DM. The blockade of immune checkpoints in cancer immu- notherapy. Nat Rev Cancer 2012;12:252–64.
[18]
Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti- PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455–65.
[19]
Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443–54.
[20]
Powles T, Eder JP, Fine GD, et al. MPDL3280A (anti-PD-L1) treat- ment leads to clinical activity in metastatic bladder cancer. Nature 2014;515:558–62.[21]
Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.[22]
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evalua- tion criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228–47.[23]
Bellmunt J, De Wit R, Vaughn DJ, et al. Pembrolizumab as second- line therapy for advanced urothelial carcinoma. N Engl J Med 2017;376:1015–26.
[24]
Choueiri TK, Fishman MN, Escudier B, et al. Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma. Clin Cancer Res 2016;22:5461–71.[25]
Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol 2015;33:1430–7.
[26]
Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373:1803–13.
[27]
Beer TM, Kwon ED, Drake CG, et al. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol 2017;35:40–7.
[28]
Kwon ED, Drake CG, Scher HI, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant pros- tate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2014;15:700–12.
[29]
Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of muta- tional processes in human cancer. Nature 2013;500:415–21.
[30]
Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 2017;389:67–76.
[31]
Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016;387:1909–20.[32]
Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 2017;18:312–22.
[33]
Balar AV, Castellano DE, O’Donnell PH, et al. Pembrolizumab as first-line therapy in cisplatin-ineligible advanced urothelial cancer: results from the total KEYNOTE-052 study population. Genitouri- nary Cancers Symposium (ASCO-GU) 2017.
[34]
De Santis M, Bellmunt J, Mead G, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/ vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 2012;30:191–9.
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 4 1 1 – 4 2 3
422